Regenerx Biopharm In Stock Book Value Per Share
| RGRXDelisted Stock | USD 0.03 0.01 25.00% |
Regenerx Biopharm In fundamentals help investors to digest information that contributes to Regenerx Biopharm's financial success or failures. It also enables traders to predict the movement of Regenerx OTC Stock. The fundamental analysis module provides a way to measure Regenerx Biopharm's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Regenerx Biopharm otc stock.
Regenerx |
Regenerx Biopharm In OTC Stock Book Value Per Share Analysis
Regenerx Biopharm's Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.
More About Book Value Per Share | All Equity Analysis
Book Value per Share | = | Common EquityAverage Shares |
Current Regenerx Biopharm Book Value Per Share | (0.02) X |
Most of Regenerx Biopharm's fundamental indicators, such as Book Value Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Regenerx Biopharm In is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
The naive approach to look at Book Value per Share is to compare it to current stock price. If Book Value per Share is higher than the currently traded stock price, the company can be considered undervalued. However, investors must be aware that conventional calculation of Book Value does not include intangible assets such as goodwill, intellectual property, trademarks or brands and may not be an appropriate measure for many firms.
CompetitionIn accordance with the recently published financial statements, the book value per share of Regenerx Biopharm In is about -0.022 times. This is 98.71% lower than that of the Biotechnology sector and 99.99% lower than that of the Health Care industry. The book value per share for all United States stocks is 100.0% higher than that of the company.
Regenerx Book Value Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Regenerx Biopharm's direct or indirect competition against its Book Value Per Share to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Regenerx Biopharm could also be used in its relative valuation, which is a method of valuing Regenerx Biopharm by comparing valuation metrics of similar companies.Regenerx Biopharm is currently under evaluation in book value per share category among its peers.
Regenerx Fundamentals
| Return On Asset | -0.84 | ||||
| Operating Margin | (19.03) % | ||||
| Current Valuation | 22.91 M | ||||
| Shares Outstanding | 143.55 M | ||||
| Shares Owned By Insiders | 45.99 % | ||||
| Shares Owned By Institutions | 0.01 % | ||||
| Number Of Shares Shorted | 19.19 K | ||||
| Price To Earning | 17.73 X | ||||
| Price To Sales | 261.81 X | ||||
| Revenue | 76.76 K | ||||
| Gross Profit | 70.12 K | ||||
| EBITDA | (1.27 M) | ||||
| Net Income | (1.6 M) | ||||
| Cash And Equivalents | 478.41 K | ||||
| Total Debt | 1.14 M | ||||
| Current Ratio | 1.05 X | ||||
| Book Value Per Share | (0.02) X | ||||
| Cash Flow From Operations | (990.3 K) | ||||
| Short Ratio | 0.15 X | ||||
| Earnings Per Share | (0.01) X | ||||
| Target Price | 1.5 | ||||
| Beta | 0.54 | ||||
| Market Capitalization | 20.1 M | ||||
| Total Asset | 1.28 M | ||||
| Retained Earnings | (105.27 M) | ||||
| Working Capital | 806 K | ||||
| Current Asset | 1.19 M | ||||
| Current Liabilities | 382 K | ||||
| Net Asset | 1.28 M |
About Regenerx Biopharm Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Regenerx Biopharm In's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Regenerx Biopharm using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Regenerx Biopharm In based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Other Consideration for investing in Regenerx OTC Stock
If you are still planning to invest in Regenerx Biopharm check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Regenerx Biopharm's history and understand the potential risks before investing.
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing |